All In Biotech

Drug Trial Radar · NCT02062060

Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

A Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Last checked: Nov 20, 2026Latest source record: May 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

325

Actual

Start

Feb 2014

Primary completion

Jul 2014

Study completion Aug 2014

Sponsor

Sponsor type
Industry
Collaborators
Accelovance; Syneos Health
First posted
Feb 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose of this study is to evaluate the efficacy of at-home administration of a single application of abametapir lotion 0.74% w/w for the treatment of head lice.

Conditions

  • Head Lice Infestation

Interventions

  • Abametapir Lotion 0.74% w/wDrug

  • Vehicle LotionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of index subjects who are lice-free at all follow-up visits through to the Day 14 visit.Time frame: 14 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Cactus Kids Pediatrics

    Yuma, Arizona

  • Axis Clinical Trials

    Los Angeles, California

  • Radiant Reserach

    Pinellas Park, Florida

  • Spence Medical Reserach

    Picayune, Mississippi

  • Haywood Pediatric

    Clyde, North Carolina

  • LSRN Research

    Nashville, Tennessee

  • Wee Care Pediatrics

    Layton, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.